Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?
Boulanger
Henri
H
Department of Nephrology and Transplantation, Saint-Louis Hospital, 1 avenue Claude-Vellefaux, 75475 Paris Cedex 10, France. henri.boulanger@sls.aphp.fr
Mansouri
Rafik
R
Gautier
Jean François
JF
Glotz
Denis
D
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003928:Diabetic Nephropathies / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004195:Disease Models, Animal; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D007674:Kidney Diseases / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists* / Q000097:blood; D045162:Thiazolidinediones / Q000494:pharmacology / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D047492:Peroxisome Proliferator-Activated Receptors; D045162:Thiazolidinediones